Palo Alto Investors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Palo Alto Investors’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-33,212	Closed	-$266K	–	41
2021 Q3	$266K	Hold	33,212	–	–	0.02%	40
2021 Q2	$377K	Hold	33,212	–	–	0.02%	39
2021 Q1	$307K	Sell	33,212 -1	-0%	-$10	0.02%	40
2020 Q4	$231K	Hold	33,213	–	–	0.01%	40
2020 Q3	$145K	Sell	33,213 -1	-0%	-$9	0.01%	42
2020 Q2	$306K	Hold	33,214	–	–	0.02%	39
2020 Q1	$482K	Hold	33,214	–	–	0.04%	32
2019 Q4	$393K	Hold	33,214	–	–	0.02%	32
2019 Q3	$837K	Hold	33,214	–	–	0.06%	31
2019 Q2	$845K	Hold	33,214	–	–	0.04%	32
2019 Q1	$1.41M	Hold	33,214	–	–	0.06%	31
2018 Q4	$483K	Hold	33,214	–	–	0.03%	32
2018 Q3	$2.33M	Hold	33,214	–	–	0.09%	29
2018 Q2	$2.46M	Hold	33,214	–	–	0.1%	29
2018 Q1	$3.16M	Hold	33,214	–	–	0.14%	28
2017 Q4	$4.29M	Hold	33,214	–	–	0.18%	29
2017 Q3	$2.25M	Hold	33,214	–	–	0.1%	30
2017 Q2	$3.14M	Hold	33,214	–	–	0.15%	27
2017 Q1	$4.77M	Hold	33,214	–	–	0.23%	26
2016 Q4	$4.21M	Hold	33,214	–	–	0.24%	26
2016 Q3	$5.08M	Hold	33,214	–	–	0.3%	29
2016 Q2	$3.82M	Hold	33,214	–	–	0.29%	31
2016 Q1	$3.77M	Hold	33,214	–	–	0.29%	31
2015 Q4	$6.26M	Hold	33,214	–	–	0.35%	28
2015 Q3	$5.65M	Buy	33,214 +28,898	+670%	+$10.4M	0.27%	32
2015 Q2	$2.73M	Buy	4,316 +1,443	+50%	+$767K	0.12%	36
2015 Q1	$1.48M	Buy	+2,873	New	+$1.45M	0.07%	40

Other funds holding VIRX

RP Management New York $139M AUM 37.98% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Palo Alto Investors's VIRX Position: Q4 2021 in Review

Palo Alto Investors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2021, closing a stake of 33,212 shares — an estimated $266K sold.

Palo Alto Investors first reported a position in VIRX in Q1 2015 and held it in 27 quarters. The position peaked at $6.26M in Q4 2015. 69 funds tracked by Wall St. Rank hold VIRX as of Q4 2021.

Palo Alto Investors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Palo Alto Investors sold 33,212 Viracta Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $266K.
Palo Alto Investors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2015 and held it in 27 quarters.
Palo Alto Investors's Viracta Therapeutics, Inc. Common Stock position peaked at $6.26M in Q4 2015.
69 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Palo Alto Investors's 13F filing for Q4 2021, filed 14 Feb 2022.